Mvix (mirodenafil)
Mvix and mirodenafil: historical Korean development, tablet versus film evidence and the limits of current product identification.
- Active ingredient
- Mirodenafil
- Form
- Tablet; orally disintegrating film
- Historical developer
- SK Chemicals Life Science (South Korea)
Mvix is the mirodenafil family developed by SK Chemicals in South Korea. The company still lists the Mvix S ODF film in 50 and 100 mg strengths among its products. Tablet and orally dispersible film presentations have distinct evidence. The company listing is not a Korean register record, so the authorization of each presentation should still be matched locally.
The film is a separate research question
A randomized study of 129 men compared 50 and 100 mg film with placebo over eight weeks. Only the 100 mg group showed a significant difference from placebo on the primary erectile-function questionnaire. Secondary outcomes were mixed, and most reported treatment-associated adverse events were mild.
The trial supports discussion of that film formulation. It does not establish faster onset than an ordinary mirodenafil tablet because the study did not directly compare them. A film can be convenient without every advertised absorption advantage being demonstrated.
What still needs a current product match
Published development and trial records are not current pharmacy stock checks. The exact Korean product, formulation, company role and local authorization should be matched before using this profile as a supply record. A statement in a dated paper about the markets known to its authors is also not a fresh worldwide register search.
The mirodenafil article explains the trial endpoint, uncertain lower-strength result and blood-timing estimates. Those estimates should not be converted into an exact erection duration. As with other PDE5 treatments, cardiovascular suitability, nitrates and other medicines belong in the clinical review, regardless of whether the product is swallowed or dissolved.
Product record
- Company
- SK Chemicals, which lists Mvix S ODF (mirodenafil 50 and 100 mg) among its current products; the Korean register entry was not checked here
- Strengths
- 50 and 100 mg investigated presentations; exact current supplied tablet/film needs a matching record
- Market
- South Korean development and study context; current exact product record needs confirmation
- Treatment area
- Erectile dysfunction (ED)
- Record reviewed
- 4 October 2026; source retrieval dates are retained with the evidence
Research and historical development are not a current registration, stock check or worldwide authorization assessment.
About mirodenafil
Mirodenafil film research offers useful formulation-specific evidence from Korean patients. Convenience is different from proven superiority to tablets. Historical development and trial amounts do not identify every current supplied product.
Using a PDE5 inhibitor safely
Never take a PDE5 inhibitor with nitrates, recreational nitrites (“poppers”) or riociguat, and do not combine two ED medicines. Seek urgent medical help for chest pain, an erection lasting more than four hours, or sudden loss of vision or hearing.
Common side effects include headache, flushing, indigestion and a blocked nose.
Sources
6 sources
Checked .
- The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts (J Clin Med, 2020) — Europe PMC
- Efficacy and Safety of Mirodenafil Oro-Dispersible Film in Korean Patients with ED (World J Mens Health, 2022) — Europe PMC
- Mirodenafil for the treatment of erectile dysfunction: a systematic review (World J Mens Health, 2014) — Europe PMC
- Efficacy and safety of mirodenafil for treatment of erectile dysfunction (J Sex Med, 2008) — Europe PMC
- Mirodenafil film randomized trial — World Journal of Men’s Health
- Mvix S ODF product page — SK Chemicals